Ianalumab plus a thrombopoietin receptor drug for primary immune thrombocytopenia
Tests how well ianalumab with another medicine is tolerated in adults with immune thrombocytopenia.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Billings, Chandler, Covington, Durham, East Brunswick, Fayetteville, Fort Worth, Hinsdale, Jacksonville, Kansas City, Margate, Miami, New Haven, Orlando, Philadelphia, Pittsburgh, Rochester, Salt Lake City, Sioux Falls, Stamford, Summit, The Bronx, and Torrance, United StatesSee the 23 sites
- Trial code
- Registry title
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 164 people, planned
- Started
- 4 Aug 2026
- Expected to end
- 31 Aug 2030
- Type of study
- Interventional, 2 groups
- Treatments tested
- ianalumab
- thrombopoietin receptor agonist (TPO-RA)
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with primary immune thrombocytopenia (ITP, low platelets caused by the immune system) or primary Evans syndrome. They get ianalumab together with a TPO-RA drug that boosts platelets.
- Age
- 18 years and older.
- Sex
- All sexes.
- Disease stage
- ITP group: primary ITP that responded to corticosteroids or IVIG, but the response did not last. Evans syndrome group: primary Evans syndrome with low platelets (< 100 G/L) and warm autoimmune hemolytic anemia (wAIHA, the immune system destroys red blood cells).
- Earlier treatment
- ITP group: at least one prior ITP treatment, no more than 4. Must be on a stable TPO-RA dose for at least 14 days before ianalumab. Evans group: poor response or relapse after corticosteroids; wAIHA supportive care stable for at least 4 weeks. Cannot join if on TPO-RA for > 6 months, or B-cell depleting therapy (e.g. rituximab, belimumab) within 12 weeks.
- Biomarker or test result
- ITP group: platelet count < 100 G/L while on a TPO-RA. Evans group: platelets < 100 G/L and a current or past positive direct antiglobulin test (DAT) (IgG+, with or without C3+) with signs of red cell breakdown.
Main reasons for not taking part
- Current life-threatening bleeding, or life-threatening red cell breakdown in the Evans group.
- Spleen removed within 6 months before ianalumab.
- No response to a standard course of rituximab.
- Secondary ITP or secondary Evans syndrome, immune deficiency, or positive HIV test.
- Abnormal lab results, such as neutrophils < 1000/mm3, IgG < 5 g/L, or serious liver disease (Child-Pugh 7 to 15).
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Signed informed consent must be obtained prior to participation in the study
- Patients aged 18 years and older on the day of signing the informed consent
- ITP cohort only: Confirmed diagnosis of primary ITP that has previously responded to corticosteroid treatment or IVIG treatment but the response was not sustained (response is defined as a platelet count ≥ 50 G/L)
- ITP cohort only: Received at least one prior treatment for ITP
- ITP cohort only: Patients with a platelet count < 100 G/L who are receiving a TPO-RA. Patients may already be receiving a TPO-RA or may start a TPO-RA at the time of screening. All patients should be on a stable dose of TPO-RA for at least 14 days prior to first dose of ianalumab. Note: during the screening period, a documented assessment of platelets < 100 G/L is mandatory for enrollment. For patients who received rescue medication before screening, platelet count results obtained prior to the start of the rescue therapy should be used to assess eligibility if collected within 14 days prior to screening
- ES cohort only: Patients with clinical diagnosis of primary ES with active thrombocytopenia (< 100 G/L) with warm autoimmune hemolytic anemia (wAIHA) for whom a TPO-RA is appropriate per Investigator
- ES cohort only: Inadequate response to or relapse after treatment with corticosteroid therapy
- ES cohort only: Diagnosis confirmed by current or past positive direct antiglobulin test (DAT) (IgG+, with or without C3+) and evidence of hemolysis
- ES cohort only: any supportive care treatment administered for wAIHA must be stable for at least 4 weeks prior to enrollment
Who cannot take part
- Patients being treated with TPO-RA for > 6 months
- Prior splenectomy within 6 months of first administration of ianalumab
- Patients exposed to more than 4 prior treatments for ITP
- ITP cohort: Use of immunosuppressant drugs other than corticosteroids or rituximab
- Current life-threatening bleeding (related to thrombocytopenia)
- Patients with significantly compromised liver disease (Child-Pugh 7 to 9) and decompensated liver disease (Child-Pugh 10 to 15)
- History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes
- Known history of primary or secondary immunodeficiency, or a positive human immunodeficiency virus (HIV) enzyme-linked immunosorbent assay (ELISA) and Western blot) test result
- ES cohort only: patients with autoimmune hemolytic anemia other than wAIHA
- Patients with the following laboratory abnormalities:; Neutrophils: < 1000/mm3; Serum creatinine > 1.5 × upper limit of normal (ULN); Aspartate aminotransferase (AST) > 3.0 × ULN; Alanine aminotransferase (ALT) > 3.0 × ULN; Immunoglobulin G (IgG) < 5 g/L; ITP cohort only: hemoglobin < 10 g/L, total bilirubin > 1.5 × ULN
- Treatment with a B-cell depleting therapy (e.g. rituximab or anti-B cell Activating Factor (e.g. belimumab) within 12 weeks prior to the first administration of ianalumab. Patients who are refractory to rituximab will be excluded from this trial, where refractory is defined as:; ~ Patients who have not achieved a response (defined as platelet count ≥ 30 G/L and at least doubling from baseline within 12 weeks in the absence of rescue therapy) following completion of a standard course of rituximab
- ITP cohort only: Diagnosis of secondary thrombocytopenia
- ES cohort only: Diagnosis of secondary ES
- ES cohort only: Life-threatening hemolysis
Where in United States
- Intermountain HealthcareBillings, United StatesContact: Cyndi BowmanTaking people
- Ironwood Cancer and Research CentersChandler, United StatesContact: Ashley MercerTaking people
- Pontchartrain Cancer CenterCovington, United StatesContact: McKenna ChaneyTaking people
- Duke University Medical CenterDurham, United StatesContact: Kristin ByrneTaking people
- Astera Cancer CenterEast Brunswick, United StatesContact: Carina CedenoTaking people
- Highlands Oncology GroupFayetteville, United StatesContact: Connor RayTaking people
- JPS Health NetworkFort Worth, United StatesContact: Melissa LillardTaking people
- Hope and Healing CareHinsdale, United StatesContact: Asma JabeenTaking people
- Baptist MD Anderson Cancer CenterJacksonville, United StatesContact: Seth WallerTaking people
- University Health Kansas CityKansas City, United StatesContact: Richard Dugan-StarrTaking people
- DH Cancer Research Center LLCMargate, United StatesContact: Maria PenaTaking people
- University of MiamiMiami, United StatesContact: Tania RodriguezTaking people
- Yale Cancer CenterNew Haven, United StatesContact: Betsy SeguiTaking people
- Advent Health OrlandoOrlando, United StatesContact: Kristen WingTaking people
- Hospital of the University of Pennsylvania Health SystemPhiladelphia, United StatesContact: Emmanuel NdukwudimmaTaking people
- Western Pennsylvania HospitalPittsburgh, United StatesContact: Brandy InceTaking people
- Mayo Clinic - RochesterRochester, United StatesContact: Aaron LittlefieldTaking people
- Utah Cancer SpecialistsSalt Lake City, United StatesContact: Emra KazicTaking people
- Avera Cancer InstituteSioux Falls, United StatesContact: Sydney SchultzTaking people
- Stamford HospitalStamford, United StatesContact: Tiffany MariscalTaking people
- Summit Medical GroupSummit, United StatesContact: Michelle MackenzieTaking people
- Montefiore Medical CenterThe Bronx, United StatesContact: Akhil AakunuriTaking people
- Harbor-UCLA Medical CenterTorrance, United StatesContact: Abisay OrtegaTaking people
About the trial
What the trial wants to find out
The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.
The 2 groups in the trial
- Main cohort: Primary immune thrombocytopenia (ITP)Treatment being tested
All participants will be assigned to ianalumab 9 mg/kg plus investigator's choice thrombopoietin receptor agonist (IC TPO-RA).
Treatment: ianalumab and thrombopoietin receptor agonist (TPO-RA)
- Exploratory cohort: Primary Evans syndrome (ES)Treatment being tested
All participants will be assigned to ianalumab 9 mg/kg plus investigator's choice thrombopoietin receptor agonist (IC TPO-RA).
Treatment: ianalumab and thrombopoietin receptor agonist (TPO-RA)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)
- Plain-language title
- Ianalumab plus a thrombopoietin receptor drug for primary immune thrombocytopeniaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 6 November 2026